4-[5-[2-(difluoromethoxy)-4-(trifluoromethyl)phenyl]pyrido[2,3-d]pyridazin-8-yl]-2,6-dimethylmorpholine
C21H19F5N4O2 — CID 174225660
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-[5-[2-(difluoromethoxy)-4-(trifluoromethyl)phenyl]pyrido[2,3-d]pyridazin-8-yl]-2,6-dimethylmorpholine
4-[5-[2-(difluoromethoxy)-4-(trifluoromethyl)phenyl]pyrido[2,3-d]pyridazin-8-yl]-2,6-dimethylmorpholine (PubChem CID 174225660) has the molecular formula C21H19F5N4O2 and a molecular weight of 454.40 g/mol. Its IUPAC name is 4-[5-[2-(difluoromethoxy)-4-(trifluoromethyl)phenyl]pyrido[2,3-d]pyridazin-8-yl]-2,6-dimethylmorpholine.
Molecular Properties
| Compound Name | 4-[5-[2-(difluoromethoxy)-4-(trifluoromethyl)phenyl]pyrido[2,3-d]pyridazin-8-yl]-2,6-dimethylmorpholine |
|---|---|
| PubChem CID | 174225660 |
| Molecular Formula | C21H19F5N4O2 |
| Molecular Weight | 454.40 g/mol |
| Exact Mass | 454.14 |
| IUPAC Name | 4-[5-[2-(difluoromethoxy)-4-(trifluoromethyl)phenyl]pyrido[2,3-d]pyridazin-8-yl]-2,6-dimethylmorpholine |
| SMILES | CC1CN(c2nnc(-c3ccc(C(F)(F)F)cc3OC(F)F)c3cccnc23)CC(C)O1 |
| InChI | InChI=1S/C21H19F5N4O2/c1-11-9-30(10-12(2)31-11)19-18-15(4-3-7-27-18)17(28-29-19)14-6-5-13(21(24,25)26)8-16(14)32-20(22)23/h3-8,11-12,20H,9-10H2,1-2H3 |
| InChIKey | WKBBVRHCOIPIES-UHFFFAOYSA-N |
| XLogP | 4.93 |
| TPSA | 60.37 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 32 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 454.40 |
| LogP ≤ 5 | 4.93 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 174225660 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.